Press release
Investors who lost money with Akero Therapeutics, Inc. (NASDAQ: AKRO) should contact the Shareholders Foundation in connection with a pending Investigation
An investigation for investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares over potential securities laws violations.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Akero Therapeutics, Inc. (NASDAQ: AKRO) concerning whether a series of statements by Akero Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
San Francisco, CA based Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. Akero Therapeutics, Inc. (NASDAQ: AKRO
On October 10, 2023, Akero Therapeutics, Inc posted interim data from its Phase 2b SYMMETRY trial for its lead candidate efruxifermin ("EFX") in patients with liver disorder nonalcoholic steatohepatitis ("NASH"). Specifically, the Company stated that 22% (28mg) and 24% (50mg) of those on EFX and 14% on placebo indicated at least one stage improvement in fibrosis with no worsening of NASH at week 36, the trial's primary endpoint, but that these changes were not statistically significant. In addition, Akero Therapeutics, Inc added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events.
Shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) declined from $58.00 per share in June 2023, to as low as $11.25 per share on October 27, 2023.
Those who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investors who lost money with Akero Therapeutics, Inc. (NASDAQ: AKRO) should contact the Shareholders Foundation in connection with a pending Investigation here
News-ID: 3456813 • Views: …
More Releases from Shareholders Foundation, Inc.
Fiserv, Inc. (NYSE: FI) Investor Alert: Deadline in Lawsuit on September 22, 202 …
A deadline is coming up on September 22, 2025 in the lawsuit filed for certain investors of Fiserv, Inc. (NYSE: FI) over alleged securities laws violations by Fiserv, Inc.
Investors who purchased shares of Fiserv, Inc. (NYSE: FI) have certain options and there are strict and short deadlines running. Deadline: September 22, 2025. Fiserv, Inc. (NYSE: FI) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Investigation announced for Long-Term Investors in Rocket Pharmaceuticals, Inc. …
An investigation was announced for current long-term investors in shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) concerning potential breaches of fiduciary duties by certain directors of Rocket Pharmaceuticals, Inc..
Investors who are current long term investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Lawsuit filed for Investors who lost money with shares of LifeMD, Inc. (NASDAQ: …
An investor, who purchased shares of LifeMD, Inc. (NASDAQ: LFMD), filed a lawsuit over alleged violations of Federal Securities Laws by LifeMD, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and for certain investors are short and strict deadlines running. Deadline: October 27, 2025. NASDAQ: LFMD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Alto Neuroscience, Inc. (NYSE: ANRO) Investor Alert: Deadline in Lawsuit on Sept …
A deadline is coming up on September 19, 2025 in the lawsuit filed for certain investors of Alto Neuroscience, Inc. (NYSE: ANRO) over alleged securities laws violations by Alto Neuroscience, Inc.
Investors who purchased shares of Alto Neuroscience, Inc. (NYSE: ANRO) have certain options and there are strict and short deadlines running. Deadline: September 19, 2025. Alto Neuroscience, Inc. (NYSE: ANRO) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
More Releases for Akero
Liver Fibrosis Market Set to Grow Substantially Through 2034, DelveInsight Proje …
DelveInsight's "Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The…
Investigation announced for Long-Term Investors in shares of Akero Therapeutics, …
An investigation was announced for current long-term investors in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) concerning potential breaches of fiduciary duties by certain directors of Akero Therapeutics, Inc.
Investors who are current long term investors in Akero Therapeutics, Inc. (NASDAQ: AKRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Liver Cirrhosis Market Key Trends, Leading Players, and Future Projections Secto …
The Global liver cirrhosis market is estimated to be valued at USD 1.41 Billion in 2024 and is expected to reach USD 2.03 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
CoherentMI has released a statistical report titled "Liver Cirrhosis Market Recent Trends, In-depth Analysis, Size, and Forecast 2024-2031." This report offers a comprehensive overview of the competitive landscape, geographical segmentation,…
Deadline on June 25th coming up in Lawsuit for Investors who lost money with sha …
A deadline is coming up on June 25, 2024 in the lawsuit filed for certain investors of Akero Therapeutics, Inc. (NASDAQ: AKRO) over alleged securities laws violations by Akero Therapeutics, Inc. (NASDAQ: AKRO).
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and there are strict and short deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors who lost money with shares of Akero Therapeutics, In …
An investor, who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO), filed a lawsuit over alleged violations of Federal Securities Laws by Akero Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) have certain options and for certain investors are short and strict deadlines running. Deadline: June 25, 2024. NASDAQ: AKRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Sales Mapping Software Market Growth Rate, Share, Overview, Future Scope, and Ke …
The Sales Mapping Software Market report encompasses an exhaustive qualitative and quantitative evaluation. The study includes growth trends, micro- and macro-economic indicators, regulations, and governmental policies. The Sales Mapping Software Market report analyses each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants determine the sub-segments be tapped into to achieve growth in the coming years.
Click Here For a Free…
